This study synthesized the current evidence on combined therapy with CD19 and CD20 or CD22 CAR T-cells and compared the efficacy and safety of combining CD19 with CD20 or CD22 CAR T-cells for the treatment of hematological malignancies. This evidence concerns the gene CD22 and hematologic disorder.